NOVA.SA has an architectural role in your equity success

NOVA.SA is a Transaction and Strategy advisory boutique located at the heart of Western-Europe, in Marcq-en-Baroeul next to Lille, France (30 minutes from Brussels, 1.5 hours from London, and 1 hour from Paris).

NOVA.SA’s name comes from latin words “novare” (innovate) and “sanitas” (health). It sets the company’s purpose in pushing innovation in healthcare forward with the goal to better treat patients and grant them access to better treatments faster and at scale. More specifically, NOVA.SA’s mission is to help healthcare innovators and investment processes move forward.

NOVA.SA has an ecosystem responsibility and has developed a structured approach around review of innovative companies and dealmaking.

It lies on a unique expertise in Healthcare and Financing, built across pharmaceutical education, and experiences in VC, investment bank, incubators, and startups.

NOVA.SA aims to define the best value-creation strategy and the best development roadmap to get to the best ROIs.

It offers solid expertise in presenting and assessing investment cases thanks to an objective, 360-degree analysis of companies in the healthcare sector, as well as a proven track record in dealmaking.

OUr eNGInE: Excellence & expertise

Excellence, Expertise, Qualité

NOVA.SA’s engine is forged in relentless expertise and uncompromising excellence, centered on maximizing the equity success of healthcare innovators.

We combine deep sector knowledge, rigorous analytic skills, and a hands-on commitment to strategic value creation. We also work with an ecosystem of experts to provide you with the best advices to drive up the value creation.

NOVA.SA supports promising innovations in their transition into high-growth equity outcomes.

Headshot of a smiling man in a black turtleneck against a dark background.

Ambition and energy to support your EQUITY ADVENTURE

Guillaume Colin (Founder, Managing Director), is a pharmacist (Pharm.D) specialized in healthcare innovation. He dedicates his professional career to biotech and healthcare deep‑tech approaches that are scientifically demanding and hard to decode, to offer breakthrough opportunities for patients.

He specifically creates value for innovative healthcare companies by combining scientific rigor and deep human values in addition to his strategy and transaction advisory experience, proposing a playbook of services from strategy to successful fundraising and exit.

Experience highlights:

  • Strategic fundraiser and advisor with deep domain expertise in pharmaceuticals and health tech

  • Advised 30+ companies across Biotech, Biotech tool, Synbio, Medtech, diagnostic, TechBio

  • Secured 10+ term sheets through targeted investor outreach, valuation framing and pitch refinement

  • Involved in 5+ closings, coordinating due diligence to drive swift execution.

  • Involved in transactions totaling over €65M in closed capital, from seed to growth-stage financings, up to M&A.